Sen. Grassley Plans Legislation On Independence Of FDA Drug Safety Office
This article was originally published in The Pink Sheet Daily
Executive Summary
Finance Committee chair acknowledges he does not have enough votes for such legislation but says he is starting the "process of educating my colleagues" and "intends to continue that until we get this job done." Grassley's requested GAO report on the Office of Drug Safety will take several months.
You may also be interested in...
FDA Post-Marketing Clinical Trial Authority Should Be Bolstered, Topol Says
Cleveland Clinic researcher Topol's suggestion is part of a JAMA editorial critical of COX-2s following Pfizer's announcement that Celebrex demonstrated an increased cardiovascular risk in a cancer trial. Topol advocates for second-line use and a contraindication in high-risk patients.
FDA Post-Marketing Clinical Trial Authority Should Be Bolstered, Topol Says
Cleveland Clinic researcher Topol's suggestion is part of a JAMA editorial critical of COX-2s following Pfizer's announcement that Celebrex demonstrated an increased cardiovascular risk in a cancer trial. Topol advocates for second-line use and a contraindication in high-risk patients.
Sen. Grassley Suggests 9/11-Like Commission On Drug Safety
Senate Finance Committee Chair Grassley says an independent commission of experts could provide recommendations to the executive branch and Congress. "It seems the time has come for a comprehensive review of drug safety," he says.